For some years, hearing aid manufacturers of all sizes have been anticipating the upcoming US sales channel, which will allow for cheaper, less advanced hearing aids to be sold over the counter (OTC).
Industry people are asking themselves: Will this lead to lower average sales prices and competition from new players, for example from low-cost manufacturers and electronics firms eyeing an opportunity to enter a market that has seemed impenetrable up until now? Or will it simply expand the market?
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
EMA publishes new plan to support antibiotic development
Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.
Carb-X secures USD 370m in fight against antibiotic resistance
International antibiotic alliance Carb-X has received commitments of up to USD 370m to accelerate the development of new antibiotics to combat a future shortage. The news is welcomed by several players on the AMR field.
Laboratory technician for process development and clinical manufacturing 
Cell Culture Scientist/Senior Scientist 
Innovation Project Manager, Display Unit 
IRT Manager, Clinical Drug Supply 
Key Account Manager, Europe and Asia 
Communications Consultant 
Clinical Trial Administrator 
Director Global Engineering 
Scientific Writer 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Account Manager 
Director for innovative pre-clinical testing unit 
Senior Chemical Safety Advisor 
(Senior) Drug Substance Specialist 
Client Talent Acquisition Specialist